A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13308
Abstract: The aim of this study was to assess the effect of expedited regulatory approval programs used by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), type of product (small molecule… read more here.
Keywords: anticancer drugs; review time; review; expedited regulatory ... See more keywords